/
RSS Feed
Thalidomide Adds to Multiple Myeloma Chemotherapy Benefit in Older Patients
ABSTRACT: Lancet 2006;367:825
George Canellos, Dana-Farber Cancer Institute, Boston
The combination of thalidomide together with standard agents melphalan and predisone has been found to be an effective first-line treatment for older patients with multiple myeloma. George Canellos discusses the findings published in The Lancet of an Italian multicenter study led by Antonio Palumbo from Turin.
George Canellos, Dana-Farber Cancer Institute, Boston
The combination of thalidomide together with standard agents melphalan and predisone has been found to be an effective first-line treatment for older patients with multiple myeloma. George Canellos discusses the findings published in The Lancet of an Italian multicenter study led by Antonio Palumbo from Turin.
Dasatinib Ready for Imatinib-Resistant Philadelphia-Chromosome Positive Leukemias?
REFERENCE: AACR CP-2 Clinical Plenary Session, Monday April 3rd 2006
Charles Sawyers, University of California, Los Angeles
The BCR-ABL kinase-targeting drug dasatinib seems poised for use in patients whose Philadelphia-chromosome positive leukemias are resistant to imatinib. Charles Sawyers from the University of California gave the Clinical Plenary Session of the American Association for Cancer Research Annual Meeting in Washington, DC his assessment of study findings to date.
Charles Sawyers, University of California, Los Angeles
The BCR-ABL kinase-targeting drug dasatinib seems poised for use in patients whose Philadelphia-chromosome positive leukemias are resistant to imatinib. Charles Sawyers from the University of California gave the Clinical Plenary Session of the American Association for Cancer Research Annual Meeting in Washington, DC his assessment of study findings to date.
Cetuximab Enhances Radiation in Head and Neck Cancer
ABSTRACT: N Engl J Med 2006;354:567
James Bonner, University of Alabama, Birmingham
A combination of the epidermal growth factor receptor inhibitor cetuximab and radiotherapy has brought better responses and survival among patients with locoregionally advanced head and neck cancer. This finding is published in the New England Journal of Medicine by James Bonner and his group in Birmingham, Alabama.
James Bonner, University of Alabama, Birmingham
A combination of the epidermal growth factor receptor inhibitor cetuximab and radiotherapy has brought better responses and survival among patients with locoregionally advanced head and neck cancer. This finding is published in the New England Journal of Medicine by James Bonner and his group in Birmingham, Alabama.
Panitumomab Response and Survival in Refractory Metastatic Colorectal Cancer
REFERENCE: American Association for Cancer Research Annual Meeting, 2006, Plenary Session, Monday 3rd April
Marc Peeters, University of Ghent
A fully human anti-epidermal growth factor receptor monoclonal antibody has been investigated for treating colorectal cancer and has achieved benefits after standard therapies have failed, according to results presented at the American Association for Cancer Research Annual Meeting in Washington DC. Marc Peeters from the University of Ghent presented results from patients for whom standard therapy with fluoropyrimidine, oxaliplatin, or irinotecan had already failed.
Marc Peeters, University of Ghent
A fully human anti-epidermal growth factor receptor monoclonal antibody has been investigated for treating colorectal cancer and has achieved benefits after standard therapies have failed, according to results presented at the American Association for Cancer Research Annual Meeting in Washington DC. Marc Peeters from the University of Ghent presented results from patients for whom standard therapy with fluoropyrimidine, oxaliplatin, or irinotecan had already failed.
Preventive Vaccines Soon for Human Papillomavirus
REFERENCE: AACR Educational Sessions, Saturday April 1st 2006
Luisa Lina Villa, Ludwig Institute for Cancer Research, São Paulo, Brasil
The dream of eliminating cervical cancer was shared during an educational session of the American Association for Cancer Research Annual Meeting in Washington, DC. Luisa Lina Villa presented the latest data on the quadravalent vaccine for human papillomavirus, protective against four subtypes of the virus: the oncogenic types 16 and 18 and the wart-casuing HPV 6 and 11 subtypes.
Luisa Lina Villa, Ludwig Institute for Cancer Research, São Paulo, Brasil
The dream of eliminating cervical cancer was shared during an educational session of the American Association for Cancer Research Annual Meeting in Washington, DC. Luisa Lina Villa presented the latest data on the quadravalent vaccine for human papillomavirus, protective against four subtypes of the virus: the oncogenic types 16 and 18 and the wart-casuing HPV 6 and 11 subtypes.
[audio:https://www.audiomedica.com/podcasting/asco/060415AJOncPodcastFINAL.mp3]
